Developer docs
API playgroundTry for free, no card

Search company profiles

Mindbloom

Full company profile

uuid00051oz

Namestring
Mindbloom
Legal namestring
Mindbloom, Inc.
Websiteurl
mindbloom.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Mindbloom is a U.S.-based, venture capital-backed telehealth platform founded in 2018 by Dylan Beynon that provides at-home, clinician-prescribed ketamine-assisted therapy for adults with anxiety, depression, PTSD, prolonged grief disorder, burnout, and other mental health conditions. The platform pairs individuals with licensed psychiatric clinicians (operating through a network of affiliated PC medical entities across five jurisdictions) who conduct telehealth evaluations and prescribe personalized ketamine treatment plans using either sublingual tablets or subcutaneous injectables. At-home administration is enabled by a standardized Bloombox kit containing a digital blood pressure monitor, AI-powered mobile app features (BloomBuddy, Voice Journaling) for session preparation and integration, required peer treatment monitoring, and guide coaching via 1:1 messaging and group integration circles.

The underlying technology stack is a HIPAA-style compliant telehealth platform with AI-augmented clinical documentation (integrations with OpenAI, Fireflies.ai, Zoom AI, Upheal, and Intercom Fin), plus applied machine learning on real-world treatment outcomes data. Mindbloom claims the two largest published peer-reviewed studies of ketamine therapy to date, including a 2022 Journal of Affective Disorders publication and a 13,963-patient sleep outcomes analysis, and operates in 36 states reaching approximately 84% of the U.S. population with 800,000+ therapy sessions facilitated cumulatively.

The business model is a direct-to-consumer, cash-pay subscription program priced at approximately 75% less than IV ketamine clinic alternatives, with out-of-network insurance reimbursement supported via superbill submission across Anthem, Aetna, United Healthcare, Cigna, Kaiser, and Blue Cross Blue Shield, and HSA/FSA payment accepted. Customer acquisition relies on content marketing, SEO, organic social media, podcast appearances by leadership, earned media, and an affiliate program. Mindbloom has raised hundreds of millions of dollars from Tier 1 VCs (Founders Fund, Kleiner Perkins, 8VC, Delphi VC, among others) across disclosed rounds in 2020 and 2021, employs 400+ personnel ('Bloomineers') on a remote-first basis, and faces an active wrongful death lawsuit (Phillip Ward) related to alleged screening failures that represents a material regulatory and reputational overhang.

Short descriptiontext

Mindbloom is a U.S. telehealth platform founded in 2018 that provides at-home, clinician-prescribed ketamine-assisted therapy for adults with anxiety, depression, PTSD, and related mental health conditions across 36 states, supported by an AI-powered mobile app and a subscription-based cash-pay model with insurance reimbursement optionality.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ketamine therapy, at-home telehealth, psychedelic medicine, mental health treatment, sublingual ketamine
Industry3 codes
PRIMARYHLALAEAB
Psychiatry & Medication Management Platforms
Healthcare & Life Sciences/Telehealth Platforms/Behavioral & Mental Health Teletherapy Platforms
SECONDARYHLALAEAA
General Mental Health Therapy Platforms (Talk Therapy)
Healthcare & Life Sciences/Telehealth Platforms/Behavioral & Mental Health Teletherapy Platforms
SECONDARYHLAFACAA
Outpatient Mental Health Clinics & Counseling Centers
Healthcare & Life Sciences/Healthcare Providers & Systems/Behavioral Health & Substance Use Treatment
NAICS code3 codes
  • Offices of Physicians, Mental Health Specialists621112
  • Outpatient Mental Health and Substance Abuse Centers621420
  • Offices of Mental Health Practitioners (except Physicians)621330
SIC code2 codes
  • Services-Health Services8000
  • Services-Offices & Clinics Of Doctors Of Medicine8011
Product category
Telehealth Mental Health Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Ketamine Therapy Program Subscriptions
TypeSubscription Recurring
Description

Recurring subscription-based access to at-home ketamine therapy programs including clinician consultations, guide support, medication, and app-based tools. Clients can seek insurance reimbursement via superbill submission for out-of-network benefits. HSA/FSA funds also accepted.

mindbloom.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1At-home ketamine therapy program with clinician support, guide coaching, and medication
ModelSubscriptionBilling cadenceMonthly
Notes

Exact pricing not publicly disclosed; positioned as significantly more affordable than IV ketamine clinic treatments (75% less). Insurance reimbursement possible via superbill for out-of-network benefits.

mindbloom.com
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

Mindbloom provides at-home, clinician-prescribed ketamine therapy via a telehealth platform for adults with anxiety, depression, PTSD, and related mental health conditions. The program pairs clients with licensed psychiatric clinicians who evaluate, prescribe, and monitor treatment using sublingual tablets or subcutaneous injectables, supported by AI-powered mobile app tools, guide coaching, and structured integration content. Treatment is delivered in 36 U.S. states with insurance reimbursement support via superbill and HSA/FSA payment acceptance.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 89% of clients report improvement in depression and anxiety symptoms after 4 sessions
+7 more records
Product overview1 text field

Mindbloom is a telehealth platform offering at-home ketamine-assisted therapy for mental health conditions. The core offering consists of a unified therapy program that provides clinician-guided ketamine treatment (available as sublingual Tablets or subcutaneous Injectables) paired with licensed psychiatric clinicians, AI-powered mobile app features (BloomBuddy), guide coaching, peer treatment monitoring, and structured integration support. The platform spans condition-specific programs for anxiety, depression, PTSD, burnout, grief, and other focus areas, and has facilitated over 800,000 sessions across 36 states. The company publishes peer-reviewed clinical outcomes and operates the Mindbloom Shop for merchandise. Insurance reimbursement support is available through superbill generation for out-of-network benefits.

Product and service9 records
1Mindbloom At-Home Ketamine Therapy Program
CategoryCore Therapy Program
Description

Telehealth-based at-home ketamine-assisted therapy program pairing individuals with licensed clinicians for diagnosis and treatment of anxiety, depression, PTSD, and other mental health conditions. Includes medical evaluation, personalized treatment plans, guided sessions, and ongoing clinician monitoring.

2Mindbloom Tablets (Sublingual Ketamine)
CategoryMedication Form Factor
Description

Sublingual ketamine tablets administered under the tongue or between cheek and gums for 7 minutes, then spit out. Part of the at-home ketamine therapy program offering for adults with treatment-resistant mental health conditions.

3Mindbloom Injectables (Subcutaneous Ketamine)
CategoryMedication Form Factor
Description

Subcutaneous ketamine injection treatment offering as an alternative to sublingual tablets. Marketed as a premium at-home form factor, with reported 81% client preference over tablets.

4Anxiety Program
CategoryCondition-Specific Program
Description

Ketamine therapy program targeting anxiety symptoms, with outcomes data showing GAD-7 response and remission rates from peer-reviewed research.

5Depression Program
CategoryCondition-Specific Program
Description

Ketamine therapy program targeting depression symptoms, with outcomes data showing PHQ-9 response and remission rates.

6PTSD Program
CategoryCondition-Specific Program
Description

Ketamine therapy program targeting PTSD symptoms, including PCL-5 response and remission rates from Mindbloom's outcomes research.

7Mindbloom 101 Program
CategoryCondition-Specific Program
Description

Introductory program for new clients covering foundational knowledge about psychedelic therapy and Mindbloom's approach.

8Telehealth Eligibility and Onboarding
CategoryClinical Service
Description

Self-service eligibility quiz and onboarding via welcome.mindbloom.com with telehealth clinical evaluation by licensed psychiatric clinicians who prescribe personalized ketamine treatment plans via video consultation.

9Mindbloom Shop
CategoryMerchandise
Description

E-commerce store for Mindbloom merchandise and products.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
Strategic tierCoreTypeGTM or Marketing Partner
Description

Insurance provider through which clients may receive reimbursement for Mindbloom ketamine therapy treatments, covering over 50% of program costs for eligible members.

Strategic tierCoreTypeGTM or Marketing Partner
Description

Insurance provider through which clients may receive reimbursement for Mindbloom ketamine therapy treatments.

Strategic tierCoreTypeGTM or Marketing Partner
Description

Insurance provider through which clients may receive reimbursement for Mindbloom ketamine therapy treatments.

Strategic tierCoreTypeGTM or Marketing Partner
Description

Insurance provider through which clients may receive reimbursement for Mindbloom ketamine therapy treatments.

Strategic tierCoreTypeGTM or Marketing Partner
Description

Insurance provider through which clients may receive reimbursement for Mindbloom ketamine therapy treatments.

Strategic tierCoreTypeGTM or Marketing Partner
Description

Insurance provider through which clients may receive reimbursement for Mindbloom ketamine therapy treatments.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Research collaboration with Cleveland Clinic psychiatry department on peer-reviewed ketamine therapy study published in Journal of Affective Disorders. Co-authors from Cleveland Clinic contributed to landmark outcomes research.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Research collaboration with UCSF psychiatry department on peer-reviewed ketamine therapy study published in Journal of Affective Disorders.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Research collaboration with NYU Langone Health on peer-reviewed ketamine therapy study published in Journal of Affective Disorders.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Research collaboration with Houston Methodist on peer-reviewed ketamine therapy study published in Journal of Affective Disorders.

Strategic tierCoreTypeTechnology or Integration
Description

Integration of OpenAI technology into BloomBuddy tool for transcription and clinical documentation support within the Mindbloom app.

Strategic tierSupportingTypeTechnology or Integration
Description

AI tool used to transcribe video meetings for purposes of creating clinical notes and quality assurance.

Strategic tierSupportingTypeTechnology or Integration
Description

AI tool for clinical documentation, supporting clinician workflow and session record-keeping.

Strategic tierSupportingTypeTechnology or Integration
Description

Video conferencing platform with AI transcription and analysis capabilities for clinical documentation and protocol compliance.

15Intercom
Strategic tierSupportingTypeTechnology or Integration
Description

Customer support chatbot (Fin AI-Powered Chatbot) addressing customer inquiries on the website.

mindbloom.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
1Nue Life Health
TypeDirect peer
Description

Nue Life is a direct at-home ketamine therapy competitor offering telehealth-led treatment programs with preparation and integration support, closely matching Mindbloom's core model and customer profile.

TypeDirect peer
Description

Innerwell is a direct at-home ketamine therapy provider offering psychiatrist-led programs with integration support, targeting similar treatment-resistant depression and anxiety populations as Mindbloom.

3Field Trip Health
TypeDirect peer
Description

Field Trip Health operated a national network of ketamine therapy clinics and was widely cited alongside Mindbloom as a key market player; it has since restructured and is pivoting toward at-home and virtual models that overlap directly with Mindbloom.

4Better U
TypeDirect peer
Description

Better U is a direct at-home ketamine therapy provider operating a virtual model with clinician-prescribed treatment, closely paralleling Mindbloom's telehealth-led DTC approach.

TypeDirect peer
Description

Wondermed is an at-home ketamine therapy provider with clinician-led programs and integration support, targeting similar patient demographics and competing in the same direct-to-consumer telehealth channel as Mindbloom.

TypeBroad incumbent
Description

Hims & Hers is a large incumbent telehealth platform that has expanded into mental health prescribing (including anxiety and depression). It offers overlapping capabilities as a broader consumer health brand, but does not specialize in ketamine therapy.

TypeBroad incumbent
Description

Cerebral is a digital mental health platform offering online psychiatric evaluation and prescription treatment for anxiety and depression, overlapping with Mindbloom's behavioral health prescribing category at a broader scale.

8Spravato (Johnson & Johnson)
TypeBroad incumbent
Description

Spravato is the FDA-approved esketamine nasal spray for treatment-resistant depression marketed by J&J. It is the principal FDA-approved ketamine-based therapy and competes with Mindbloom for the same patient population, but requires in-clinic administration under REMS.

TypeEmerging player
Description

Compass Pathways is a clinical-stage psychedelic therapy company developing psilocybin treatment for treatment-resistant depression. It targets the same underlying patient need as Mindbloom and represents the next generation of FDA-approved psychedelic alternatives.

TypeBroad incumbent
Description

Talkspace is a large incumbent online therapy and psychiatry platform serving similar behavioral health consumers with both therapy and medication management, overlapping in target market but differing in modality (talk therapy vs. ketamine).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration5 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mindbloom

Telehealth Mental Health Servicesmindbloom.com

Mindbloom is a U.S. telehealth platform founded in 2018 that provides at-home, clinician-prescribed ketamine-assisted therapy for adults with anxiety, depression, PTSD, and related mental health conditions across 36 states, supported by an AI-powered mobile app and a subscription-based cash-pay model with insurance reimbursement optionality.

What Mindbloom does

Mindbloom is a U.S.-based, venture capital-backed telehealth platform founded in 2018 by Dylan Beynon that provides at-home, clinician-prescribed ketamine-assisted therapy for adults with anxiety, depression, PTSD, prolonged grief disorder, burnout, and other mental health conditions. The platform pairs individuals with licensed psychiatric clinicians (operating through a network of affiliated PC medical entities across five jurisdictions) who conduct telehealth evaluations and prescribe personalized ketamine treatment plans using either sublingual tablets or subcutaneous injectables. At-home administration is enabled by a standardized Bloombox kit containing a digital blood pressure monitor, AI-powered mobile app features (BloomBuddy, Voice Journaling) for session preparation and integration, required peer treatment monitoring, and guide coaching via 1:1 messaging and group integration circles.

The underlying technology stack is a HIPAA-style compliant telehealth platform with AI-augmented clinical documentation (integrations with OpenAI, Fireflies.ai, Zoom AI, Upheal, and Intercom Fin), plus applied machine learning on real-world treatment outcomes data. Mindbloom claims the two largest published peer-reviewed studies of ketamine therapy to date, including a 2022 Journal of Affective Disorders publication and a 13,963-patient sleep outcomes analysis, and operates in 36 states reaching approximately 84% of the U.S. population with 800,000+ therapy sessions facilitated cumulatively.

The business model is a direct-to-consumer, cash-pay subscription program priced at approximately 75% less than IV ketamine clinic alternatives, with out-of-network insurance reimbursement supported via superbill submission across Anthem, Aetna, United Healthcare, Cigna, Kaiser, and Blue Cross Blue Shield, and HSA/FSA payment accepted. Customer acquisition relies on content marketing, SEO, organic social media, podcast appearances by leadership, earned media, and an affiliate program. Mindbloom has raised hundreds of millions of dollars from Tier 1 VCs (Founders Fund, Kleiner Perkins, 8VC, Delphi VC, among others) across disclosed rounds in 2020 and 2021, employs 400+ personnel ('Bloomineers') on a remote-first basis, and faces an active wrongful death lawsuit (Phillip Ward) related to alleged screening failures that represents a material regulatory and reputational overhang.

Mindbloom firmographics

Firmographics
Name
Mindbloom
Legal name
Mindbloom, Inc.
Website
https://mindbloom.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
101–250 employees
Short description
Mindbloom is a U.S. telehealth platform founded in 2018 that provides at-home, clinician-prescribed ketamine-assisted therapy for adults with anxiety, depression, PTSD, and related mental health conditions across 36 states, supported by an AI-powered mobile app and a subscription-based cash-pay model with insurance reimbursement optionality.
Ownership category
akta.pro rank

Mindbloom industry classification

Industry
Product category
Telehealth Mental Health Services
NAICS
Offices of Physicians, Mental Health Specialists (621112), Outpatient Mental Health and Substance Abuse Centers (621420), Offices of Mental Health Practitioners (except Physicians) (621330)
SIC
Services-Health Services (8000), Services-Offices & Clinics Of Doctors Of Medicine (8011)
akta.pro industry
PRIMARYHLALAEAB
Psychiatry & Medication Management Platforms
Healthcare & Life Sciences/Telehealth Platforms/Behavioral & Mental Health Teletherapy Platforms
SECONDARYHLALAEAA
General Mental Health Therapy Platforms (Talk Therapy)
Healthcare & Life Sciences/Telehealth Platforms/Behavioral & Mental Health Teletherapy Platforms
SECONDARYHLAFACAA
Outpatient Mental Health Clinics & Counseling Centers
Healthcare & Life Sciences/Healthcare Providers & Systems/Behavioral Health & Substance Use Treatment

Keywords

  • Ketamine therapy
  • At-home telehealth
  • Psychedelic medicine
  • Mental health treatment
  • Sublingual ketamine

Where Mindbloom is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Mindbloom business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Ketamine Therapy Program Subscriptions: Recurring subscription-based access to at-home ketamine therapy programs including clinician consultations, guide support, medication, and app-based tools. Clients can seek insurance reimbursement via superbill submission for out-of-network benefits. HSA/FSA funds also accepted.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyAt-home ketamine therapy program with clinician support, guide coaching, and medication

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Mindbloom product offering

Product offering

Core offering

Mindbloom provides at-home, clinician-prescribed ketamine therapy via a telehealth platform for adults with anxiety, depression, PTSD, and related mental health conditions. The program pairs clients with licensed psychiatric clinicians who evaluate, prescribe, and monitor treatment using sublingual tablets or subcutaneous injectables, supported by AI-powered mobile app tools, guide coaching, and structured integration content. Treatment is delivered in 36 U.S. states with insurance reimbursement support via superbill and HSA/FSA payment acceptance.

Product overview

Mindbloom is a telehealth platform offering at-home ketamine-assisted therapy for mental health conditions. The core offering consists of a unified therapy program that provides clinician-guided ketamine treatment (available as sublingual Tablets or subcutaneous Injectables) paired with licensed psychiatric clinicians, AI-powered mobile app features (BloomBuddy), guide coaching, peer treatment monitoring, and structured integration support. The platform spans condition-specific programs for anxiety, depression, PTSD, burnout, grief, and other focus areas, and has facilitated over 800,000 sessions across 36 states. The company publishes peer-reviewed clinical outcomes and operates the Mindbloom Shop for merchandise. Insurance reimbursement support is available through superbill generation for out-of-network benefits.

Differentiator

Problem solved

Functional benefit

Products and services

  • Mindbloom At-Home Ketamine Therapy Program Telehealth-based at-home ketamine-assisted therapy program pairing individuals with licensed clinicians for diagnosis and treatment of anxiety, depression, PTSD, and other mental health conditions. Includes medical evaluation, personalized treatment plans, guided sessions, and ongoing clinician monitoring.
  • Mindbloom Tablets (Sublingual Ketamine) Sublingual ketamine tablets administered under the tongue or between cheek and gums for 7 minutes, then spit out. Part of the at-home ketamine therapy program offering for adults with treatment-resistant mental health conditions.
  • Mindbloom Injectables (Subcutaneous Ketamine) Subcutaneous ketamine injection treatment offering as an alternative to sublingual tablets. Marketed as a premium at-home form factor, with reported 81% client preference over tablets.
  • Anxiety Program Ketamine therapy program targeting anxiety symptoms, with outcomes data showing GAD-7 response and remission rates from peer-reviewed research.
  • Depression Program Ketamine therapy program targeting depression symptoms, with outcomes data showing PHQ-9 response and remission rates.
  • PTSD Program Ketamine therapy program targeting PTSD symptoms, including PCL-5 response and remission rates from Mindbloom's outcomes research.
  • Mindbloom 101 Program Introductory program for new clients covering foundational knowledge about psychedelic therapy and Mindbloom's approach.
  • Telehealth Eligibility and Onboarding Self-service eligibility quiz and onboarding via welcome.mindbloom.com with telehealth clinical evaluation by licensed psychiatric clinicians who prescribe personalized ketamine treatment plans via video consultation.
  • Mindbloom Shop E-commerce store for Mindbloom merchandise and products.

Quantifiable outcome

  • 89% of clients report improvement in depression and anxiety symptoms after 4 sessions
  • +7 more outcomes

Companies that use Mindbloom

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Mindbloom technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability7 records

Feature5 records

Mindbloom partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered core, major and supporting.

  • AnthemcoreGTM or Marketing PartnerInsurance provider through which clients may receive reimbursement for Mindbloom ketamine therapy treatments, covering over 50% of program costs for eligible members.
  • AetnacoreGTM or Marketing PartnerInsurance provider through which clients may receive reimbursement for Mindbloom ketamine therapy treatments.
  • United HealthcarecoreGTM or Marketing PartnerInsurance provider through which clients may receive reimbursement for Mindbloom ketamine therapy treatments.
  • CignacoreGTM or Marketing PartnerInsurance provider through which clients may receive reimbursement for Mindbloom ketamine therapy treatments.
  • KaisercoreGTM or Marketing PartnerInsurance provider through which clients may receive reimbursement for Mindbloom ketamine therapy treatments.
  • Blue Cross Blue ShieldcoreGTM or Marketing PartnerInsurance provider through which clients may receive reimbursement for Mindbloom ketamine therapy treatments.
  • Cleveland ClinicmajorStrategic or Co-development PartnerResearch collaboration with Cleveland Clinic psychiatry department on peer-reviewed ketamine therapy study published in Journal of Affective Disorders. Co-authors from Cleveland Clinic contributed to landmark outcomes research.
  • UCSFmajorStrategic or Co-development PartnerResearch collaboration with UCSF psychiatry department on peer-reviewed ketamine therapy study published in Journal of Affective Disorders.
  • NYUmajorStrategic or Co-development PartnerResearch collaboration with NYU Langone Health on peer-reviewed ketamine therapy study published in Journal of Affective Disorders.
  • Houston MethodistmajorStrategic or Co-development PartnerResearch collaboration with Houston Methodist on peer-reviewed ketamine therapy study published in Journal of Affective Disorders.
  • OpenAIcoreTechnology or IntegrationIntegration of OpenAI technology into BloomBuddy tool for transcription and clinical documentation support within the Mindbloom app.
  • Fireflies.aisupportingTechnology or IntegrationAI tool used to transcribe video meetings for purposes of creating clinical notes and quality assurance.
  • UphealsupportingTechnology or IntegrationAI tool for clinical documentation, supporting clinician workflow and session record-keeping.
  • ZoomsupportingTechnology or IntegrationVideo conferencing platform with AI transcription and analysis capabilities for clinical documentation and protocol compliance.
  • IntercomsupportingTechnology or IntegrationCustomer support chatbot (Fin AI-Powered Chatbot) addressing customer inquiries on the website.

Scale indicators10 records

Recent moves6 records

Expansion highlights7 records

Mindbloom competitors and assessment

Company assessment

Direct peers

  • Nue Life Health: Nue Life is a direct at-home ketamine therapy competitor offering telehealth-led treatment programs with preparation and integration support, closely matching Mindbloom's core model and customer profile.
  • Innerwell: Innerwell is a direct at-home ketamine therapy provider offering psychiatrist-led programs with integration support, targeting similar treatment-resistant depression and anxiety populations as Mindbloom.
  • Field Trip Health: Field Trip Health operated a national network of ketamine therapy clinics and was widely cited alongside Mindbloom as a key market player; it has since restructured and is pivoting toward at-home and virtual models that overlap directly with Mindbloom.
  • Better U: Better U is a direct at-home ketamine therapy provider operating a virtual model with clinician-prescribed treatment, closely paralleling Mindbloom's telehealth-led DTC approach.
  • Wondermed: Wondermed is an at-home ketamine therapy provider with clinician-led programs and integration support, targeting similar patient demographics and competing in the same direct-to-consumer telehealth channel as Mindbloom.

Broad incumbents

  • Hims & Hers Health: Hims & Hers is a large incumbent telehealth platform that has expanded into mental health prescribing (including anxiety and depression). It offers overlapping capabilities as a broader consumer health brand, but does not specialize in ketamine therapy.
  • Cerebral: Cerebral is a digital mental health platform offering online psychiatric evaluation and prescription treatment for anxiety and depression, overlapping with Mindbloom's behavioral health prescribing category at a broader scale.
  • Spravato (Johnson & Johnson): Spravato is the FDA-approved esketamine nasal spray for treatment-resistant depression marketed by J&J. It is the principal FDA-approved ketamine-based therapy and competes with Mindbloom for the same patient population, but requires in-clinic administration under REMS.
  • Talkspace: Talkspace is a large incumbent online therapy and psychiatry platform serving similar behavioral health consumers with both therapy and medication management, overlapping in target market but differing in modality (talk therapy vs. ketamine).

Emerging players

  • Compass Pathways: Compass Pathways is a clinical-stage psychedelic therapy company developing psilocybin treatment for treatment-resistant depression. It targets the same underlying patient need as Mindbloom and represents the next generation of FDA-approved psychedelic alternatives.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Mindbloom social profiles

Digital presence

Mindbloom compliance and trust

Trust signal

Compliance2 records

Mindbloom financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mindbloom leadership team

Management profile

Number of profiles

Profiles9 records

Mindbloom subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

Mindbloom funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mindbloom M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mindbloom

What does Mindbloom do?

Mindbloom provides at-home, clinician-prescribed ketamine therapy via a telehealth platform for adults with anxiety, depression, PTSD, and related mental health conditions. The program pairs clients with licensed psychiatric clinicians who evaluate, prescribe, and monitor treatment using sublingual tablets or subcutaneous injectables, supported by AI-powered mobile app tools, guide coaching, and structured integration content. Treatment is delivered in 36 U.S. states with insurance reimbursement support via superbill and HSA/FSA payment acceptance.

Is Mindbloom a public or private company?

Mindbloom is a private company. It is classified as venture growth investor backed and is currently operating.

When was Mindbloom founded?

Mindbloom was founded in 2018. It employs 101 to 250 people.

Where is Mindbloom based?

Mindbloom is headquartered in New York, United States, in the North America region.

How does Mindbloom make money?

One revenue line is on record: ketamine Therapy Program Subscriptions.

Who are Mindbloom's main competitors?

Direct peers on record are Nue Life Health, Innerwell, Field Trip Health, Better U and Wondermed. Broad incumbents are Hims & Hers Health, Cerebral, Spravato (Johnson & Johnson) and Talkspace. Compass Pathways is listed as an emerging player.

Does Mindbloom have an API?

No public API is recorded for Mindbloom.

What industry is Mindbloom in?

Mindbloom's product category is Telehealth Mental Health Services. Its primary akta.pro industry code is HLALAEAB, Psychiatry & Medication Management Platforms, with a secondary code of HLALAEAA, General Mental Health Therapy Platforms (Talk Therapy). Its NAICS code is 621112 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooMassive data breach exposes private therapy patient recordsMindbloom Provider Group PA disclosed a data breach to the Vermont Attorney General, exposing private therapy patient records including diagnoses, treatment plans, clinical notes, prescriptions, and insurance data. The company has not released details on how the breach was discovered or when it occurred. Affected patients are advised to contact Mindbloom directly for updates and protection resources.MindbloomOutcomes & Evidence: Ketamine and Psychedelic TherapyMindbloom has published outcomes analyses of its at-home ketamine-assisted therapy program for conditions including prolonged grief disorder, depression, anxiety, and sleep difficulties, anchored by peer-reviewed research in the Journal of Affective Disorders.BhbusinessWhat Trump’s Executive Order on Psychedelics for PTSD, SMI Signals for the IndustryPresident Trump signed an executive order accelerating FDA approvals for psychedelic treatments for PTSD, depression, and substance use, mandating $50 million in funding. The order expands Right to Try pathways but does not de-schedule substances, and experts expect increased provider participation and investment. Industry reactions vary, with some companies seeing stock gains.Coherent Market InsightsKetamine Clinic Market Size, Share and Forecast, 2026-2033The global ketamine clinic market is projected to grow from USD 1.60 billion in 2026 to USD 3.42 billion by 2033, driven by an 11.4% CAGR, rising treatment-resistant depression prevalence, and increasing acceptance of psychedelic-assisted therapies. North America leads the market with a 37.3% share, while Asia Pacific emerges as the fastest-growing region at 25.2%. Key developments include U.S. FDA warnings on compounded ketamine safety, technological advancements in AI-driven monitoring and telemedicine, and strategic moves by companies like Field Trip Health, Mindbloom, and Johnson & Johnson's Spravato approval.BhbusinessPE Plays It Safe in Psychedelic Investments While Venture Goes BoldPrivate equity remains cautious on psychedelic-assisted therapy investments due to regulatory uncertainty and reimbursement challenges, while venture capital continues to fund the sector. Lykos Therapeutics raised $50 million in a Series B round, and Mindbloom has raised $44.9 million. Experts expect FDA approvals for MDMA or psilocybin within two years, which could attract more PE interest.YahooOne of Elon Musk’s DOGE Staffers Used to Sell Ketamine ProfessionallyDOGE staffer Alexandra Beynon previously led engineering at Mindbloom, a ketamine therapy company, before joining the Department of Education. Musk has admitted using ketamine for depression, and the drug is not FDA-approved for mental health use.PR NewswireMindbloom and Happier Break New Ground with the Ultimate Fusion of Ketamine Therapy and MindfulnessMindbloom and Happier announced a partnership to combine ketamine therapy with mindfulness, giving Mindbloom clients free access to Happier's guided meditations and Happier users discounted access to Mindbloom's programs. The partnership cites 62% of Mindbloom clients reporting significant improvements after four sessions. Phase two, launching next year, will integrate Happier meditations into the Mindbloom app.WsjPeople Are Injecting Ketamine at HomeMindbloom, a startup that mails ketamine to patients' homes, has added injectable doses to its product line. Doctors say this increases risks of misuse and diversion into the illicit market, as ketamine is unapproved for psychiatric use.WsjPeople Are Injecting Ketamine at HomeMindbloom, a startup that mails ketamine to homes, added injectable doses to its product line. Doctors say this makes the risky practice riskier, as ketamine is an unapproved anesthetic for psychiatric conditions and can be addictive and diverted.PR NewswireMindbloom Launches Expert-Led Psychedelic Therapy for PTSDMindbloom launched a ketamine therapy program for PTSD, combining its protocol with trauma expert Shari Botwin's content. The program includes six sessions on topics like guilt and shame, plus coaching and integration circles. Mindbloom facilitates over 275,000 at-home ketamine sessions annually.